Entamoeba histolytica, a protozoan intestinal parasite, is the causative agent of human amebiasis. Amebiasis is the fourth leading cause of death and the third leading cause of morbidity due to protozoan infections worldwide 1 , resulting in ~70,000 deaths annually. E. histolytica has been listed by the National Institutes of Health as a category B priority biodefense pathogen in the United States. Treatment relies on metronidazole 2 , which has adverse effects 3 , and potential resistance of E. histolytica to the drug is an increasing concern 4,5 . To facilitate drug screening for this anaerobic protozoan, we developed and validated an automated, highthroughput screen (HTS). This screen identified auranofin, a US Food and Drug Administration (FDA)-approved drug used therapeutically for rheumatoid arthritis, as active against E. histolytica in culture. Auranofin was ten times more potent against E. histolytica than metronidazole. Transcriptional profiling and thioredoxin reductase assays suggested that auranofin targets the E. histolytica thioredoxin reductase, preventing the reduction of thioredoxin and enhancing sensitivity of trophozoites to reactive oxygen-mediated killing. In a mouse model of amebic colitis and a hamster model of amebic liver abscess, oral auranofin markedly decreased the number of parasites, the detrimental host inflammatory response and hepatic damage. This new use of auranofin represents a promising therapy for amebiasis, and the drug has been granted orphan-drug status from the FDA.
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Screening large chemical libraries to identify amebicidals has been hindered by the throughput of labor-intensive traditional assays that rely on microscopic visualization 6 , radioisotopes 7 and/or extensive staining methods 8 . We developed and employed an automated HTS that is suitable for rapid and more efficient screening of large, diverse inhibitor libraries for activity against E. histolytica. The challenges of developing the HTS platform for E. histolytica included the facts that it is an anaerobe and that no rapid readout assay is available. We solved these issues by using GasPak EZ Anaerobe Gas Generating Pouch Systems and the CellTiter-Glo Luminescent Cell Viability Assay. The GasPak was not needed during robotic transfers, making this assay fully compatible with workstation-based automation. We developed the assay with exponentially growing E. histolytica trophozoites plated at 50,000 parasites per milliliter in 96-well 8 or 30,000 parasites per milliliter in 384-well microtiter plates. We maintained anaerobic conditions using GasPak during growth. As ATP is an essential cofactor for biogenesis in E. histolytica, we used the CellTiter-Glo luciferasebased assay to validate the correlation between the number of viable trophozoites and their ATP levels. The relationship between numbers of parasites seeded into 96-and 384-well plates and relative luminescence from CellTiter-Glo assaying of parasites showed a linear correlation (R 2 = 0.86 and R 2 = 0.9) (Fig. 1a,b) . Trophozoites readily tolerated up to 0.5% DMSO, used to dissolve the compounds, with no effect on growth rate (data not shown). In our system, the halfmaximal effective concentration (EC 50 ) for metronidazole, defined as that concentration of compound necessary to reduce the culture density to 50% of that of a DMSO-treated culture, was 5 µM. We used this HTS assay to evaluate the amebicidal activity of potential drug candidates, with parasites plated at 50,000 parasites per milliliter in a 96-well microtiter plate at a single concentration of 5 µM of the test compound.
We performed the screen with a 910-member Iconix library, consisting of both FDA-approved and unapproved bioactive compounds. The use of drugs already approved for human use opens the possibility to reprofile or repurpose 9 drugs to treat amebiasis in a rapid and costeffective manner; using approved compounds allows for shortened development timelines and decreased risk, as such compounds have already passed regulatory clinical trials with full toxicological and pharmacokinetic profiles 9 .
We identified 11 compounds as 'active' , causing statistically significant growth inhibition (>50%; Fig. 1c and Table 1 ). The assay showed excellent discrimination between active and inactive compounds with a Z′ (a dimensionless calculation used to assess the quality of a high-throughput assay) of 0.96 ± 0.13 in the screening experiment using 12 different plates containing the Iconix library compounds. Among the 11 compounds, auranofin had the highest amebicidal activity with an EC 50 of 0.5 µM, tenfold better than that of metronidazole. Auranofin purchased from another manufacturer and three auranofin analogs also inhibited growth of E. histolytica trophozoites (Supplementary Table 1) . Two purine analogs, cladribine and fludarabine, showed 79% and 77% growth inhibition, respectively, at 5 µM but are not promising for further development because of reported adverse effects in humans. We also identified trifluoperazine, a compound with known amebicidal activity 10 , as a primary hit, confirming the sensitivity of our whole-cell HTS assay format.
Auranofin is an FDA-approved oral, gold-containing drug that has been in clinical use to treat rheumatoid arthritis for 25 years and is sold as Ridaura (Prometheus). The published pharmacokinetic data of auranofin come from studies in humans with rheumatoid arthritis after long-term therapy. Auranofin is rapidly metabolized, so only the released elemental gold can be detected in human blood or tissues. Following an oral dose, 25% of auranofin (gold) is absorbed into blood, of which 60% is bound by plasma proteins 11 . Steady-state mean blood gold concentrations in humans are 0.68 ± 0.45 µg ml −1 (according to the package insert from the manufacturer) or approximately 3.5 µM, more than 7 times the in vitro EC 50 for E. histolytica. Auranofin was approved for the long-term treatment of unresponsive rheumatoid arthritis in adults with courses for a minimum of 6 months at oral doses of 3 mg once or twice daily (not adjusted for weight). The manufacturer indicates the following complications in patients treated for at least 1 year with auranofin: 47% of patients had at least one loose stool, 24% a rash, 14% an episode of abdominal pain, 13% stomatitis, 10% nausea, 3% anemia and 2% elevated liver function tests at some point. The likelihood of gold toxicity is extremely small in the standard, short-term (7-10 d) therapy for amebiasis.
Recently, auranofin has been shown to rapidly kill juvenile and adult Schistosoma mansoni in culture at concentrations achievable in patients with rheumatoid arthritis (5 µM) 12 and the bloodstream and procyclic stages of Trypanosoma brucei with half-maximal inhibitory concentration (IC 50 ) in the lower nanomolar range 13 . Concentrations as low as 2.5 µM also kill larval worms of Echinococcus granulosus in vitro 14 . Auranofin also strongly inhibits the growth of malarial parasite Plasmodium falciparum in vitro 15 and kills the promastigote stage of Leishmania infantum in vitro at micromolar concentrations 16 .
Although auranofin has been used clinically for 25 years, its mechanism of action is poorly understood. To identify the basis of auranofin's activity against E. histolytica, we undertook a transcriptional profiling study using E. histolytica oligonucleotide microarrays 17 . Incubation of E. histolytica with 1 µM auranofin for only 3 h induced downregulation of genes encoding crucial proteins involved in mitosis (Rae1 (ref . 18)) and nucleotide metabolism (nucleoside diphosphate kinase 19 ), whereas the genes encoding the signal transduction proteins ADP-ribosylation factor and Ras1p were upregulated 20 (Supplementary Table 2 ). However, these transcripts are also induced by other forms of cellular stress 21 . Furthermore, there was a marked upregulation of the gene encoding a protein similar to arsenite-inducible RNA-associated protein (AIRAP) (Supplementary Table 2 ). The differential expression of these down-and upregulated transcripts in auranofin-treated E. histolytica was validated by real-time quantitative reverse transcription PCR (qRT-PCR) ( Supplementary Fig. 1 and Supplementary Table 3) .
AIRAP is unique among known arsenite-induced genes in that its expression is not upregulated in response to other oxidants and is only modestly induced by exposure to metals, such as zinc 22 , although gold has not been tested. Our finding that the transcript for a gene similar to that encoding AIRAP in E. histolytica was highly upregulated by treatment with low concentrations of auranofin thereby identifies a 23, 24 and metabolic inhibitors of selenium metabolism 25 . This led us to hypothesize that E. histolytica TrxR is the probable target of auranofin. Because E. histolytica resides in either aerobic (liver) or anaerobic (colon) environments in its mammalian hosts, the parasite must have a means to minimize damage caused by reactive oxygen species produced by the host immune assault. In most organisms, there are two largely independent systems to detoxify reactive oxygen species, one based on glutathione and the other based on thioredoxin. Each of these systems has a dedicated NADPH-dependent flavoenzyme, glutathione reductase and TrxR, to maintain the reduced state of glutathione and thioredoxin, respectively [26] [27] [28] . However, E. histolytica lacks both glutathione reductase activity and glutathione synthetic enzymes 29 ; its TrxR is involved in prevention, intervention and repair of damage caused by oxidative stress 30 .
There is a single TrxR-encoding gene in the E. histolytica genome (EHI_155440). E. histolytica TrxR (EhTrxR) belongs to the lowmolecular-weight TrxR family 31 and is similar to bacterial and yeast enzymes, including the TrxR from Escherichia coli ( Supplementary  Fig. 2 ). In contrast, most higher eukaryotes have a high-molecularweight TrxR that is typically a selenocysteine protein; this enzyme in S. mansoni, known as TGR, has both selenium and an appended glutaredoxin domain 24 (Supplementary Fig. 3) . We hypothesized that EhTrxR would not contain selenium and that auranofin would bind the active-site cysteines. We were able to readily purify active, His-tagged EhTrxR from solubilized E. coli by nickel-affinity chromatography 30 for use in inhibition studies.
We examined the activities of auranofin and its two most active analogs for inhibition of recombinant EhTrxR. Low-micromolar concentrations of auranofin and analog 39 and nanomolar concentrations of analog 7 were inhibitory (Fig. 2a-c) . The assays were nonlinear for the first 50 s (shown for auranofin in the inset of Fig. 2a at concentrations of 0, 0.25, 0.5, 0.75, 1, 2 and 5 µM, in order of decreasing slope), unlike control reactions without auranofin; inhibition increased with time until a linear, inhibited rate was established after 50 s of reaction (Fig. 2a) . Examination of the rates after 50 s indicated that 0.4 µM auranofin caused 50% inhibition. The EC 50 values for analog 39 and analog 7 were 0.33 and 0.055 µM, respectively. Preincubation of the inhibitor with reduced EhTrxR did not remove the lag phase in inhibition, as seen by the nonlinearity of the data acquired up to 50 s (data not shown).
Because TrxR is crucial for protecting amebic trophozoites from oxidant attack, we compared the susceptibility of trophozoites with and without auranofin treatment to reactive oxygen species (H 2 O 2 ). After incubation of trophozoites with 2 µM auranofin for 18 h, the remaining viable trophozoites (~50%) were significantly more sensitive to killing by 300 µM H 2 O 2 than control trophozoites in medium alone (P < 0.002) (Fig. 2d) . Killing by auranofin (2 µM) and H 2 O 2 was reversed by the presence of 2 mg ml −1 of cysteine (Fig. 2d) . Cysteine is the major reductant in E. histolytica 32 , and its apparent protective effect may be through direct reduction of thioredoxin or inhibition of auranofin binding to cysteine residues in TrxR. We detected the presence of reactive oxygen species after 2 µM auranofin treatment with fluorescence generated by the oxidation of dichlorodihydrofluorescein added to the medium 33 (Fig. 2e) . However, the same concentration of metronidazole, although producing stress, did not increase intracellular reactive oxygen species (Supplementary Fig. 4) . Moreover, we observed increased amounts of oxidized thioredoxin in auranofintreated trophozoites, both in vitro and in vivo, indicating that TrxR may be a target for auranofin (Fig. 2f) .
Recently, the crystal structure of S. mansoni TGR that had been incubated with auranofin before crystallization was solved 24 . The structure revealed gold (Au(I)) rather than auranofin as an adduct between pairs of cysteines (Cys-Au-Cys) in two different sites and also bound to the proposed NADPH binding site of the reductase in a third location. The C terminus of TGR containing a selenocysteine residue was not observed in the structure and may have bound a fourth gold atom. The authors of that study proposed that the selenocysteine at the penultimate position of TGR accelerated the release of gold from auranofin to form the inactivated enzymes; benzeneselenol added to a npg C-terminally truncated TGR or to glutathione reductase increased the rate of inactivation by auranofin 24 . The crystal structure of reduced L. infantum trypanothione reductase complexed with NADPH and auranofin also demonstrated that gold binds two active cysteine residues of trypanothione reductase 16 . EhTrxR is of very similar size and domain topology as E. coli TrxR, a well-studied enzyme 34 . Both proteins have an active site dithiol/ disulfide center (Cys-Ala-Thr-Cys for EcTrxR, Cys-Ala-Ile-Cys for EhTrxR) plus either two or four additional cysteine residues, respectively (Supplementary Fig. 2 ). By analogy with the S. mansoni TGR, addition of auranofin could cause gold atoms to bind the NADPHbinding site of EhTrxR, the active-site thiols, the four cysteine residues near the C terminus of the enzyme or some combination of these sites.
Because of auranofin's in vitro activity against E. histolytica trophozoites and oral availability, we tested its efficacy in two animal models of amebiasis. We adapted a mouse amebic colitis model in which trophozoites invade and colonize mouse cecal tissue after surgical inoculation 35, 36 . We co-cultured amebic trophozoites with cecal bacteria and surgically inoculated them into the cecum of C3H/HeJ mice. We delivered auranofin or metronidazole by gavage 24 h after infection at a concentration of 1 mg per kg body weight per day for 7 d (ref. 37) . Both the parasite burden and the inflammatory response as measured by activity of myeloperoxidase in cecal tissue were significantly decreased by auranofin (P = 0.037 and P = 0.0021, respectively) (Fig. 3a,b) but not by metronidazole (Fig. 3c,d) . Auranofin (Fig. 3e) was more effective than an equivalent dose of metronidazole (Fig. 3f ) in a hamster model of amebic liver abscess where treatment started 4 d after infection. A single oral dose of 3 mg per kg body weight per day of auranofin for 7 d significantly decreased hepatic damage in hamsters (P = 0.002) (Fig. 3e) . These findings suggest that auranofin may be an entirely new class of drug to treat amebiasis and potentially other parasitic infections. On the basis of these results, the FDA has approved an orphan-drug designation of auranofin for treatment of amebiasis.
In summary, we have shown that it is feasible to screen large numbers of compounds in an HTS format for effectiveness against E. histolytica, and robust and reproducible results can be generated from this HTS. The discovery of the amebicidal activity of the FDAapproved drug auranofin offers a promising drug-repositioning opportunity for the treatment of amebiasis.
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Methods and any associated references are available in the online version of the paper.
Accession codes. Microarray data are deposited in ArrayExpress with accession code E-MEXP-3494. npg by incubating cultured trophozoites in urea buffer with 3.5 mM DTT for 30 min at 37 °C, then equal aliquots alkylated with 30 mM iodoacetic acid (reduced marker) or 10 mM iodoacetamide (oxidized) marker for 30 min at 37 °C (ref. 38 ). Samples were electrophoresed by native urea-PAGE on 9% gels and transferred to nitrocellulose; the bands were detected with rabbit EhTrx-specific antibody 30 (1:200, a gift from S. Adrian-Guerrero) and goat antibody to rabbit IgG conjugated to horseradish peroxidase (Invitrogen, 1:10,000, catalog no. 65-6120) by enhanced chemiluminescence (SuperSignal, West Pico, Fisher Scientific).
In vivo efficacy of auranofin. We injected cecal-passed trophozoites into the externalized cecum of 6-week-old C3H/HeJ male mice 35 (Jackson Laboratory) and treated them orally 24 h after infection with 1 mg per kg body weight per day auranofin (Enzo Life Sciences) or metronidazole for 7 d. The mice were then killed, and the cecum was removed for histopathology. Trophozoites were quantified by real-time PCR, and myeloperoxidase activity was assayed 41 . Mouse studies were approved by the University of California-San Diego Institutional Animal Care Committee.
We injected trophozoites (250,000 in 0.2 mL TYI-S-33) intraportally in hamsters to induce liver abscesses. The hamsters were treated 4 d after infection orally with 3 mg per kg body weight of auranofin, metronidazole or PBS daily for 7 d. The hamsters were killed, and the livers and abscesses were dissected and weighed. Hamster studies were approved by the Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional Internal Committee for the Care and Use of the Laboratory Animals.
